VistaGen Therapeutics (VTGN) reported Q2 revenue

VistaGen Therapeutics (NASDAQ: VTGN) reported Q2 EPS of ($0.54). Revenue for the quarter came in at $258 million.

For earnings history and earnings-related data on VistaGen Therapeutics (VTGN) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• S&P Global (SPGI) Declares $0.97 Quarterly Dividend; 1% Yield
• HSBC Downgrades Hermes International (RMS:FP) (HESAY) to Hold